Salvage Treatment for Persistent Methicillin‐Resistant Staphylococcus aureus Bacteremia: Efficacy of Linezolid With or Without Carbapenem
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with high mortality rates, but no treatment strategy has yet been established. We performed this study to evaluate the efficacy of linezolid with or without carbapenem in salvage treatment for persistent MRSA bacteremia. METHODS: All adult patients with persistent MRSA bacteremia for 7 days from January 2006 through March 2008 who were treated at Seoul National University Hospital were studied. The results of linezolid salvage therapy with or without carbapenem were compared with those of salvage therapy with vancomycin plus aminoglycosides or rifampicin. RESULTS: Thirty-five patients with persistent MRSA bacteremia were studied. The early microbiological response (ie, negative results for follow-up blood culture within 72 hours) was significantly higher in the linezolid-based salvage therapy group than the comparison group (75% vs 17%; P =.006). Adding aminoglycosides or rifampicin to vancomycin was not successful in treating any of the patients, whereas linezolid-based therapy gave an 88% salvage success rate P =.001). The S. aureus-related mortality rate was lower for patients treated with a linezolid salvage regimen than for patients continually treated with a vancomycin-based regimen (13% vs 53%; P =.030). CONCLUSIONS: Linezolid-based salvage therapy effectively eradicated S. aureus from the blood for patients with persistent MRSA bacteremia. The salvage success rate was higher for linezolid therapy than for vancomycin-based combination therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Linezolid was reported to be effective in the treatment of persistent MRSA bacteremia, 172 but this study had important study design weaknesses.173”
Citations
Cites
Staphylococcus aureus Infections
Lowy, F. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390806 · Cited by 6,005
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“teremia in the United States [2].”
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860
Clinical Identifiers of Complicated Staphylococcus aureus Bacteremia
Fowler, V. G., Olsen, M. K., Corey, G. R., Woods, C. W., Cabell, C. H., Reller, L. B., Cheng, A. C., Dudley, T., & Oddone, E. Z. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.17.2066 · Cited by 652
Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/381202 · Cited by 484
Fowler, Jr., Sakoulas, G., McIntyre, L. M., Meka, V. G., Arbeit, R. D., Cabell, C. H., Stryjewski, M. E., Eliopoulos, G. M., Reller, L. B., Corey, G. R., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/423145 · Cited by 351
Jones, R. N. (2006) · Clinical Infectious Diseases · doi:10.1086/491710 · Cited by 254
Howden, B. P., Johnson, P. D. R., Ward, P. B., Stinear, T. P., & Davies, J. K. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00422-06 · Cited by 224
Jenkins, T. C., Price, C. S., Sabel, A. L., Mehler, P. S., & Burman, W. J. (2008) · Clinical Infectious Diseases · doi:10.1086/529190 · Cited by 216
Micek, S. T. (2007) · Clinical Infectious Diseases · doi:10.1086/519471 · Cited by 202
Limitations of Vancomycin in the Management of Resistant Staphylococcal Infections
Kollef, M. H. (2007) · Clinical Infectious Diseases · doi:10.1086/519470 · Cited by 178
Persistence in Staphylococcus aureus bacteremia: Incidence, characteristics of patients and outcome
Khatib, R., Johnson, L. B., Fakih, M. G., Riederer, K., Khosrovaneh, A., Shamse Tabriz, M., Sharma, M., & Saeed, S. (2006) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540500372846 · Cited by 168
Falagas, M. E., Siempos, I. I., & Vardakas, K. Z. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70312-2 · Cited by 166
Hawkins, C. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.17.1861 · Cited by 166
Adaptation of Methicillin-Resistant Staphylococcus aureus in the Face of Vancomycin Therapy
Sakoulas, G., Moellering, R. C., & Eliopoulos, G. M. (2006) · Clinical Infectious Diseases · doi:10.1086/491713 · Cited by 165
Wu, V.-C., Wang, Y.-T., Wang, C.-Y., Tsai, I.-J., Wu, K.-D., Hwang, J.-J., & Hsueh, P.-R. (2006) · Clinical Infectious Diseases · doi:10.1086/498509 · Cited by 161
Complications Associated With Staphylococcus aureus Bacteremia
Libman, H. (1984) · Archives of Internal Medicine · doi:10.1001/archinte.144.3.541 · Cited by 159
Outcome ofStaphylococcus aureusBacteremia in Patients with Eradicable Foci versus Noneradicable Foci
Kim, S., Park, W. B., Lee, K., Kang, C., Kim, H. B., Oh, M., Kim, E.-C., & Choe, K. W. (2003) · Clinical Infectious Diseases · doi:10.1086/377540 · Cited by 153
Self-citationJacqueline, C., Navas, D., Batard, E., Miegeville, A.-F., Le Mabecque, V., Kergueris, M.-F., Bugnon, D., Potel, G., & Caillon, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.45-51.2005 · Cited by 95
Moise, P. A., Forrest, A., Birmingham, M. C., & Schentag, J. J. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf215 · Cited by 94
Khosrovaneh, A., Riederer, K., Saeed, S., Tabriz, M. S., Shah, A. R., Hanna, M. M., Sharma, M., Johnson, L. B., Fakih, M. G., & Khatib, R. (2004) · Clinical Infectious Diseases · doi:10.1086/383036 · Cited by 65
Hageman, J. C., Liedtke, L. A., Sunenshine, R. H., Strausbaugh, L. J., McDonald, L. C., Tenover, F. C., & Infectious Diseases Society of America Emerging Infections Network (2006) · Clinical Infectious Diseases · doi:10.1086/506568 · Cited by 37
Jacqueline, C., Caillon, J., Grossi, O., Le Mabecque, V., Miegeville, A.-F., Bugnon, D., Batard, E., & Potel, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01501-05 · Cited by 36
You, I., Kariyama, R., Zervos, M., Kumon, H., & Chow, J. W. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00104-2 · Cited by 33
Cited by
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Predictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
Metadata
- Authors
- Jang, H., Kim, S., Kim, K. H., Kim, C. J., Lee, S., Song, K., Jeon, J. H., Park, W. B., Kim, H. B., Park, S., Kim, N. J., Kim, E., Oh, M., & Choe, K. W.
- Affiliations
- Seoul National University (KR)
- Corresponding author
- Oh, Myoung‐don
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-08
- Volume
- 49
- Issue
- 3
- Pages
- 395-401
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2170146384
- Cited by
- 113
- References
- 26
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 7 · 2019: 7 · 2018: 4 · 2017: 1 · 2016: 7 · 2015: 8 · 2014: 10 · 2013: 12 · 2012: 9
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- methicillin-resistant Staphylococcus aureus, linezolid, carbapenems, salvage therapy, vancomycin, aminoglycosides, rifampicin, combination antibiotic therapy, mortality, microbiological response
- MeSH terms
- Linezolid, Acetamides, Adolescent, Adult, Aged, Aged, 80 and over, Aminoglycosides, Anti-Bacterial Agents, Drug Therapy, Combination, Humans, Korea, Middle Aged, Staphylococcal Infections, Vancomycin, Carbapenems, Bacteremia, Salvage Therapy, Treatment Outcome, Oxazolidinones, Methicillin-Resistant Staphylococcus aureus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.